Sydney, June 19, 2026, 02:07 (AEST)
- CSL finished Thursday up 1.21% at A$108.08. The S&P/ASX 200 ended down 0.62%.
- The shares are up 5.52% for the week, but still down 54.87% over the past year.
- CSL has set August 18 to release its full-year earnings and the final dividend.
CSL Limited ended Thursday at A$108.08, up A$1.29. Shares traded between A$105.90 and A$108.44 during the session. The broader Australian index dropped 55.2 points to 8,911.1.
S&P/ASX 200 ended its four-day winning streak. Still, healthcare names gained 0.35%, with buyers stepping in for weaker medical stocks. CSL led the group, climbing faster than the broader sector.
There was no new operational news with the move. CSL’s most recent ASX update is still a June 9 administrative filing about securities. So Thursday’s buying looks more like investors adjusting positions after a sharp drop than a sign that the company’s earnings outlook is turning up.
CSL kept its May business review as its key guide for now. The company is projecting about US$15.2 billion in revenue in fiscal 2026 and NPATA of around US$3.1 billion, excluding currency swings. NPATA stands for net profit after tax before amortisation of acquired IP and significant one-offs.
Interim Chief Executive Gordon Naylor said the restructuring’s payoff is lagging expectations. “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise,” he said.
The review pointed to roughly US$5 billion in extra non-cash pre-tax impairments for fiscal 2026 and 2027. These include CSL Vifor asset write-downs and some underused property and equipment. An impairment cuts an asset’s book value without a cash outflow.
CSL’s rebound hasn’t solved its credibility problem. “Back-to-back downgrades do raise legitimate questions about the company’s visibility into its own business,” Mark Gardner, founder and chief executive of MPC Markets, said after the May update. Sahm
Morningstar equity strategist Lochlan Halloway sees immunoglobulin revenue rising around 5% a year over ten years, but said tougher prices in the plasma market could eat into CSL’s cost savings. Roche’s lab-made haemophilia drug Hemlibra also adds pressure, and Sanofi is still ahead of CSL in the flu vaccine space.
But CSL’s rebound is at risk if US immunoglobulin stockpiles stay high, Chinese albumin prices drop again or rivals hit the iron-drug segment. Delays in the second-half recovery, a bigger write-down or more time without a permanent CEO would also revive the bear case.
CSL Behring needs to prove with its August numbers that sales are picking up and that the asset review has finally put past investment missteps to rest. CSL shares traded higher on Thursday, a positive move, but not evidence of a full turnaround yet.
